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Anti-inﬂammatory activityAbstract A new series of 1,3,4-thiadiazole with pyrazole-3-carboxamides (3a–f) and pyrrole-3-car-
boxamide (4a–f) moiety are prepared using intermediate compounds 1,3,4-thiadiazolacrylamides
(2a–f). The structures of newly synthesized compounds were conﬁrmed on the basis of their 1H
NMR, 13C NMR, LCMS mass, FT-IR and elemental analysis data results. Among all the com-
pounds (12), seven compounds were found to exhibit signiﬁcant anti-inﬂammatory activity with
77.27, 75.89, 76.24, 68.55, 63.72, 57.41, 53.05% and 81.00, 80.55, 78.62, 71.45, 68.95, 61.89,
56.32% inhibition in paw edema at 3 h and 5 h respectively, compared to the standard drug indo-
methacin (74.82 and 80.32% at 3 h and 5 h). Compounds 3c, 3d and 4c exhibited potent activity
than standard drug.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inﬂammation is a complex defensive mechanism of the body to
any noxious stimulus; this process may vary from a localizedto a generalized response characterized by the accumulation
of ﬂuids and leukocytes leading to edema and pain (Cunha
et al., 2008). This inﬂammatory response seems to be mediated
by different physiological and immunological mediators that
play a role in acute and chronic inﬂammation (Kanaka
Padmanabham and Giles, 2011). Acute inﬂammation occurs
as the initial response to tissue injury, being mediated by the
release of autacoids, for example, serotonin, thromboxanes,
histamine and leukotrienes (Sherwood and Toliver-Kinsky,
2004). On the other hand, the chronic inﬂammatory process in-
volves the release of diverse mediators, as interleukins, inter-
feron and tumor necrosis factor a (TNF–a), and a cytokine
that plays a major role in this kind of inﬂammatory process
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diseases such as rheumatoid arthritis (Spirchez et al., 2012;
Mangge et al., 1995).
Non-steroidal anti-inﬂammatory drugs are commonly used
for the treatment of pain and inﬂammation associated with dif-
ferent diseases particularly rheumatoid arthritis (Patrinani
et al., 2011), however their chronic use may cause GIT ulcera-
tion, bleeding and renal injury (Wolfe et al., 1999). Therefore,
although there are a number of anti-inﬂammatory drugs avail-
able in the market, there is a need to develop novel drugs with
better safety proﬁle. 1,3,4-thiadiazoles are an important class
of heterocyclic compounds that exhibit a broad spectrum of
biological activities such as anti cancer (Badr and Barwa,
2011; Miyahara et al., 1982; Al-Soud et al., 2008), antiviral
(Chen et al., 2010; Al-Masoudi et al., 2004; Invidiata et al.,
1996), antibacterial (Maddila and Jonnalagadda, 2012; Mad-
dila et al., 2012), antioxidant (Khan et al., 2010; Shih and
Ke, 2004), anxiolytic (Invidiata et al., 1991), anti-tubercular
(Andanappa et al., 2004), anticonvulsant (Stillings et al.,
1986; Gupta et al., 2009) and anti-inﬂammatory activities
(Rostom et al., 2009; Schenone et al., 2006) etc.
In the pursuit and design of new drugs, the development of
hybrid molecules through the combination of different phar-
macophores in one frame may lead to compounds with inter-
esting biological proﬁles. Prompted by these observations, in
the present study, the synthesis and anti-inﬂammatory screen-
ing of new 1,3,4-thiadiazole derivatives incorporating with dif-
ferent pyrazole-3-carboxamide and pyrrole-3-carboxamide
moiety pharmacophores as hybrid molecules possessing anti-
inﬂammatory activity are aimed.2. Results and discussion
2.1. Chemistry
The compound (E)-3-(4-substitutedphenyl)-N-(5-phenyl-1,3,4-
thiadiazol-2-yl) acrylamide (2a–f) was synthesized via the sin-
gle step process of 5-phenyl-1,3,4-thiadiazol-2-amine with
substituted cinnamic acid in the presence of EDCÆHCl, HOBt
condition. It was then converted into 4-(4-substitutedphenyl)-
N-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-pyrazole-3-carboxam-
ides (3a–f) by cyclization with hydrazines under microwave
irradiation in the presence of sodium acetate as a catalyst to
a good yield. Reacting 1,3,4-acrylamides (2a–f) with TosMIC
(Tosylmethyl isocyanide) and NaH at room temperature re-
sulted in the formation of the corresponding 4-(4-substituted-Scheme 1 Synthetic route employed fophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-pyrrole-3-car-
boxamide (4a–f). (Scheme 1.). The structures of the newly
synthesized compounds were conﬁrmed on the basis of IR,
1H-NMR, 13C-NMR, MS spectrometry and elemental
analysis.
All the synthesized compounds gave satisfactory analyses
for the proposed structures, which were conﬁrmed on the basis
of their spectral data. The IR spectra of compounds 2a–f
exhibited characteristic absorption bands at 3315–3334 cm1,
1630–1658 cm1 and 1562–1580 cm1 for NH, CONH and
C‚N functional groups, while 1H NMR spectrum showed a
broad singlet region of NH at d 10.42–10.51, multiplet of aro-
matic rings at d 7.06–8.21 and two doublets of single protons
of ‚CH at range of d 7.06–8.21 and 6.85–7.09 ppm which
proved the synthetic nucleus 2a–f.
The IR spectra of compounds 3a–f exhibited characteristic
absorption bands at 3320–3342 cm1, 1665–1687 cm1, 1564–
1580 cm1, and 1263–1296 & 1175–1222 cm1 corresponding
to the NH, CONH, C‚N and C–S–C stretching respectively.
Similarly the 1H NMR spectra displayed peaks in the range of
d 13.70–13.76 ppm for NH, d 8.62–8.88 ppm for CONH and d
7.84–7.96 ppm for pyrazole–CH. The IR spectra of com-
pounds 4a–f revealed characteristic absorption bands at
3286–3297 cm1 for NH, 1681–1695 cm1 for CONH and
1573–1581 cm1 corresponding to C‚N stretching vibrations.
The 1H NMR spectra displayed peaks in the range of d 10.64–
10.73 ppm for NH, d 8.08–8.35 ppm for CONH and d 6.76–
6.83 & 6.70–6.77 ppm for pyrrole CH respectively. The 13C
NMR and Mass spectral data of compounds 3a–f and 4a–f
are given in the experimental section.3. Biological assay
All the synthesized compounds were evaluated for their anti-
inﬂammatory activity against carrageenan-induced acute paw
edema in Wistar albino rats weighing 150–200 g, using Ple-
thysmometer following the method of Winter (Winter et al.,
1962). The animals were weighed and divided into control,
standard, test groups each group contained six rats. The ﬁrst
group of rats was treated with 0.1 mL of 0.5% gum acacia
suspension orally (control), second group was administered
with a dose of 10 mg/kg of the suspension of indomethacin
(standard) and the test group was treated with equimolar
dose of the suspension of test compounds relative to standard
drug. After 30 min, the animals were injected with 0.1 mL of
1% carrageenan in normal saline, subcutaneously to the sub-r the synthesis of target molecules.
Table 1 Results of anti-inﬂammatory activity of 1,3,4-thiadiazoles derivatives against carrageenan induced rat paw edema model.
Compounds 3 h 5 h
Swel ± SE % inhibition Swel ± SE % inhibition
Edema induced by carrageenan (% edema inhibition relative to control)
3a 0.534 ± 0.042a 38.70 0.515 ± 0.033b 41.42
3b 0.371 ± 0.065c 57.41 0.335 ± 0.090c 61.89
3c 0.198 ± 0.049c 77.27 0.167 ± 0.084c 81.00
3d 0.210 ± 0.043c 75.89 0.171 ± 0.076c 80.55
3e 0.409 ± 0.040c 53.05 0.384 ± 0.088b 56.32
3f 0.274 ± 0.061c 68.55 0.201 ± 0.57c 71.45
4a 0.657 ± 0.051d 24.57 0.631 ± 0.042a 28.22
4b 0.510 ± 0.057d 41.45 0.486 ± 0.114b 44.71
4c 0.207 ± 0.021c 76.24 0.188 ± 0.066c 78.62
4d 0.316 ± 0.058c 63.72 0.273 ± 0.089c 68.95
4e 0.575 ± 0.091b 33.99 0.551 ± 0.074b 37.32
4f 0.463 ± 0.091a 46.85 0.398 ± 0.074c 54.73
Indomethacin 0.218 ± 0.029c 74.82 0.173 ± 0.045c 80.32
Control 0.871 ± 0.040 — 0.879 ± 0.078 —
Swel, mean difference in rat paw volume between right and left paw ± S.E; % inhibition, (1Vt/Vc) · 100; Vt, mean increase in paw volume of
test; Vc, mean increase in paw volume of control group of rats.
a p< 0.05;
b p< 0.01;
c p< 0.001 signiﬁcantly different from standard;
d ns, not signiﬁcant.
S308 S. Maddila et al.plantar region of the right hind paw. The paw volume was
measured at 0 h, 1 h, 3 h and 5 h, using plethysmometer.
The amount of edema in the drug-treated groups was com-
pared in relation to the control group with the corresponding
time intervals. Results are calculated as mean ± SEM, and
different groups were compared using one way analysis of
variance ANOVA followed by dunnet’s-t-test and results
are tabulated in Table 1.
3.1. Biological results
The results of anti-inﬂammatory activity are summarized in
Table 1. The tested compounds, 3c, 3d, 4c, 3f, 4d, 3b and 3e
were found to be active and have signiﬁcant activity (77.27,
75.89, 76.24, 68.55, 63.72, 57.41, 53.05% and 81.00, 80.55,
78.62, 71.45, 68.95, 61.89, 56.32% inhibition in paw edema
at 3 h and 5 h respectively) when compared to the standard
drug indomethacin (74.82 and 80.32% at 3 h and 5 h). Com-
pounds 3c, 3d and 4c were more active than the standard drug
indomethacin. From the biological activity data, the structural
activity relationship (SAR) can be drawn as follows. Com-
pounds having electron withdrawing group on the pyrazole-
3-carboxamide and pyrrole-3-carboxamide in 1,3,4-thiadiazole
ring. The 1,3,4-thiadiazole linked pyrazole-3-carboxamide
compounds 3a–f are responsible for better activity compared
to 1,3,4-thiadiazole linked pyrrole-3-carboxamide for com-
pounds 4a–f. Substitution of weak electron withdrawing
groups and no substituted groups on pyrazole and pyrrole at-
tached thiadiazole ring decreases the activity but is compara-
ble with the standard. Compounds having substitution like –
NO2, F group on the pyrazoles and pyrrole ring are showing
potential activity (March, 2005). Whereas the remaining com-
pounds having weak electron withdrawing groups attached on
the pyrazole and pyrrole with thiadiazoles signiﬁcantly dimin-
ish the activity. These data suggest that functionality of thepyrazole and pyrrole group is playing an important role in
the enzymatic interactions responsible for anti-inﬂammatory
activity.4. Experimental
All reagents and solvents were purchased and used without
further puriﬁcation. Melting points determined on a Fisher–
Johns melting point apparatus were uncorrected. Crude
products were puriﬁed by column chromatography on silica
gel of 60–120 mesh. The IR spectra (KBr pellets) were re-
corded on a Vertex 70 Bruker spectrometer. The NMR spectra
were recorded on a varian 300 MHz spectrometer for 1H
NMR. Carbon nuclear magnetic resonance (13C NMR) spec-
tra were recorded on Bruker 100 MHz spectrometer. The
chemical shifts were reported as ppm down ﬁeld using TMS
as an internal standard. The mass spectra of the new com-
pounds were recorded on a triple quadrupole mass spectrome-
ter Varian 1200 L/MS/MS with electrospray interface (ESI),
coupled with a high performance liquid chromatography with
Varian Prostar 240 SDM ternar pump. The instrument was
operated in positive ion mode.4.1. General procedure for the synthesis of (E)-3-(4-
substitutedphenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-
yl)acrylamide derivatives (2a–f)
A stirred solution of compound 5-phenyl-1,3,4-thiadiazol-2-
amine (1 mmol) in CH2Cl2 (50 mL) was treated with the
appropriate substituted cinnamic acid, EDCÆHCl (0.15 mmol),
HOBt (0.05 mmol) and reﬂuxed overnight. Then puriﬁcation
with recrystallization afforded the corresponding compound
as white powder.
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Yield: 88 %; mp 196–198 C; IR (t cm1, KBr): 3315 (NH),
1658 (CONH), 1628 (C‚C), 1574 (C‚N); 1H NMR
(300 MHz, DMSO-d6): d 6.86 (d, J= 15.6 Hz, 1H), 7.25–
7.58 (m, 10H, ArH), 7.64 (d, J= 15.7 Hz, 1H), 10.46 (bs,
1H, NH); (ESIMS) m/z: 308 [M+H]+. Anal. Calcd. for
C17H13N3OS: C, 66.43; H, 4.26; N, 13.67. Found: C, 66.39;
H, 4.29; N, 13.63.
4.3. (E)-3-(4-bromophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-
yl)acrylamide (2b)
Yield: 91 %; mp 175–176 C; IR (t cm1, KBr): 3327 (NH),
1630 (CONH), 1621 (C‚C), 1575 (C‚N); 1H NMR
(300 MHz, DMSO-d6): d 6.89 (d, J= 15.6 Hz, 1H), 7.18–
7.50 (m, 9H, ArH), 7.66 (d, J= 15.6 Hz, 1H), 10.42 (bs, 1H,
NH); (ESIMS) m/z: 386 [M+2H]+. Anal. Calcd. for
C17H12BrN3OS: C, 52.86; H, 3.13; N, 10.88. Found: C,
52.91; H, 3.08; N, 10.83.
4.4. (E)-3-(4-nitrophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-
yl)acrylamide (2c)
Yield: 90 %; mp 203–205 C; IR (t cm1, KBr): 3324 (NH),
1645 (CONH), 1630 (C‚C), 1562 (C‚N); 1H NMR
(300 MHz, DMSO-d6): d 7.09 (d, J= 16.2 Hz, 1H), 7.27–
8.21 (m, 9H, ArH), 7.73 (d, J= 16.2 Hz, 1H), 10.51 (bs, 1H,
NH); (ESIMS) m/z: 353 [M+H]+. Anal. Calcd. for
C17H12N4O3S: C, 57.95; H, 3.43; N, 15.90. Found: C, 57.99;
H, 3.47; N, 15.92.
4.5. (E)-3-(4-ﬂuorophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-
yl)acrylamide (2d)
Yield: 88 %; mp 169–170 C; IR (t cm1, KBr): 3322 (NH),
1641 (CONH), 1626 (C‚C), 1578 (C‚N); 1H NMR
(300 MHz, DMSO-d6): d 6.85 (d, J= 15.6 Hz, 1H), 7.06–
7.48 (m, 9H, ArH), 7.68 (d, J= 15.6 Hz, 1H), 10.47 (bs, 1H,
NH); (ESIMS) m/z: 326 [M+H]+. Anal. Calcd. for
C17H12FN3OS: C, 62.76; H, 3.72; N, 12.91. Found: C, 62.81;
H, 3.68; N, 12.95.4.6. (E)-3-(4-iodophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-
yl)acrylamide (2e)
Yield: 89 %; mp 216–218 C; IR (t cm1, KBr): 3330 (NH),
1648 (CONH), 1633 (C‚C), 1580 (C‚N); 1H NMR
(300 MHz, DMSO-d6): d 6.88 (d, J= 15.6 Hz, 1H), 7.14–7.60
(m, 9H, ArH), 7.69 (d, J= 15.6 Hz, 1H), 10.48 (bs, 1H, NH);
(ESIMS) m/z: 433 [M+H]+. Anal. Calcd. for C17H12IN3OS:
C, 47.13; H, 2.79; N, 9.70. Found: C, 47.07; H, 2.73; N, 9.77.4.7. (E)-3-(4-chlorophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-
yl)acrylamide (2f)
Yield: 90 %; mp 171–173 C; IR (t cm1, KBr): 3334 (NH),
1635 (CONH), 1627 (C‚C), 1571 (C‚N); 1H NMR(300 MHz, DMSO-d6): d 6.92 (d, J= 15.6 Hz, 1H), 7.24–
7.49 (m, 9H, ArH), 7.67 (d, J= 15.6 Hz, 1H), 10.46 (bs, 1H,
NH); (ESIMS) m/z: 342 [M+H]+. Anal. Calcd. for
C17H12ClN3OS: C, 59.73; H, 3.54; N, 12.29. Found: C,
59.77; H, 3.57; N, 12.33.4.8. General procedure for the synthesis of 4-(4-
substitutedphenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-
pyrazole-3-carboxamide derivatives (3a–f)
Equimolar amounts (1 mmol) of compound 2 and different
hydrazines were mixed in ethanolic sodium acetate (10 ml)
and reﬂuxed under microwave irradiation (140–210 W) for
about 30–35 min using a synthetic microwave oven. The reac-
tions were monitored by TLC. The mixture was concentrated
in a water bath and poured into ice-cold water. The precipitate
obtained was ﬁltered, washed, dried and puriﬁed by recrystal-
lization from ethanol.4.9. 4-Phenyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-pyrazole-
3-carboxamide (3a)
Yield: 93 %; mp 253–254 C; IR (t cm1, KBr): 3324 (NH),
1665 (CONH), 1565 (C‚N), 1283, 1195 (C–SC); 1H NMR
(300 MHz, DMSO-d6): d 7.28–7.77 (m, 10H, ArH), 7.96 (s,
1H, pyrazole-CH), 8.62 (bs, 1H, CONH), 13.76 (bs, 1H,
NH); 13C NMR (100 MHz, DMSO-d6): d 123.27, 127.78,
128.69, 130.08, 132.34, 133.47, 134.30, 137.17, 151.33, 165.48,
176.52; (ESIMS) m/z: 348 [M+H]+. Anal. Calcd. for
C18H13N5OS: C, 62.23; H, 3.77; N, 20.16. Found: C, 62.25;
H, 3.73; N, 20.19.4.10. 4-(4-Bromophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-
1H-pyrazole-3-carboxamide (3b)
Yield: 90 %; mp 214–215 C; IR (t cm1, KBr): 3328 (NH),
1673 (CONH), 1580 (C‚N), 1263, 1205 (C–SC), 630 (C–
Br); 1H NMR (300 MHz, DMSO-d6): d 7.30–7.65 (m, 9H,
ArH), 7.89 (s, 1H, pyrazole-CH), 8.67 (bs, 1H, CONH),
13.73 (bs, 1H, NH); 13C NMR (100 MHz, DMSO-d6): d
123.31, 125.07, 127.83, 128.91, 130.24, 130.51, 132.36,
133.29, 133.53, 134.41, 136.96, 151.34, 165.50, 176.73;
(ESIMS) m/z: 426 [M+H]+. Anal. Calcd. For
C18H12BrN5OS: C, 50.71; H, 2.84; N, 16.43. Found: C,
50.69; H, 2.87; N, 16.40.4.11. 4-(4-Nitrophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-
1H-pyrazole-3-carboxamide (3c)
Yield: 87 %; mp 230–232 C; IR (t cm1, KBr): 3342 (NH),
1687 (CONH), 1576 (C‚N), 1273, 1175 (C–SC); 1H NMR
(300 MHz, DMSO-d6): d 7.31–8.32 (m, 10H, ArH & pyra-
zole-CH), 8.83 (bs, 1H, CONH), 13.70 (bs, 1H, NH); 13C
NMR (100 MHz, DMSO-d6): d 120.07, 123.43, 127.84,
128.98, 129.65, 130.26, 132.33, 133.41, 133.54, 144.61, 149.23,
151.42, 165.51, 176.76; (ESIMS) m/z: 393 [M+H]+. Anal.
Calcd. for C18H12N6O3S: C, 55.10; H, 3.08; N, 21.42. Found:
C, 55.12; H, 3.11; N, 21.47.
S310 S. Maddila et al.4.12. 4-(4-Fluorophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-
1H-pyrazole-3-carboxamide (3d)
Yield: 91 %; mp 223–225 C; IR (t cm1, KBr): 3335 (NH),
1681 (CONH), 1579 (C‚N), 1313 (C–F), 1296, 1222 (C–
SC); 1H NMR (300 MHz, DMSO0-d6): d 7.32–7.65 (m,
9H, ArH), 7.84 (s, 1H, pyrazole-CH), 8.83 (bs, 1H, CONH),
13.74 (bs, 1H, NH); 13C NMR (100 MHz, DMSO-d6): d
118.13, 123.37, 127.86, 128.93, 129.41, 130.23, 132.39,
133.10, 133.53, 134.38, 151.35, 161.23, 165.49, 176.73;
(ESIMS) m/z: 366 [M+H]+. Anal. Calcd. for
C18H12FN5OS: C, 59.17; H, 3.31; N, 19.17. Found: C,
59.15; H, 3.33; N, 19.15.
4.13. 4-(4-Iodophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-
pyrazole-3-carboxamide (3e)
Yield: 95 %; mp 185–187 C; IR (t cm1, KBr): 3320 (NH),
1667 (CONH), 1564 (C‚N), 1293, 1176 (C–SC), 556 (C–
I); 1H NMR (300 MHz, DMSO-d6): d 7.29–7.76 (m, 9H,
ArH), 7.92 (s, 1H, pyrazole-CH), 8.88 (bs, 1H, CONH),
13.72 (bs, 1H, NH); 13C NMR (100 MHz, DMSO-d6): d
93.13, 123.28, 127.80, 128.91, 129.36, 130.25, 132.34, 133.47,
134.30, 136.51, 137.32, 151.27, 165.50, 176.69; (ESIMS) m/
z: 473 [M+H]+. Anal. Calcd. for C18H12IN5OS: C, 45.68;
H, 2.56; N, 14.80. Found: C, 45.71; H, 2.59; N, 14.83.
4.14. 4-(4-Chlorophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-
1H-pyrazole-3-carboxamide (3f)
Yield: 91 %; mp 217–219 C; IR (t cm1, KBr): 3330 (NH),
1671 (CONH), 1580 (C‚N), 1276, 1195 (C–SC), 710 (C–
Cl); 1H NMR (300 MHz, DMSO-d6): d 7.28–7.60 (m, 9H,
ArH), 7.87 (s, 1H, pyrazole-CH), 8.80 (bs, 1H, CONH),
13.71 (bs, 1H, NH); 13C NMR (100 MHz, DMSO-d6): d
26.82, 30.48, 54.50, 68.19, 123.74, 125.16, 126.40, 127.51,
127.58, 128.62, 130.13, 134.75, 146.82, 151.42, 153.72, 155.51,
157.29; (ESIMS) m/z: 382 [M+H]+. Anal. Calcd. for
C18H12ClN5OS: C, 56.62; H, 3.17; N, 18.34. Found: C,
56.60; H, 3.19; N, 18.37.
4.15. General procedure for the synthesis of 4-(4-
substitutedphenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-
pyrrole-3-carboxamide derivatives (4a–f)
A mixture of TosMIC (1 mmol) and 2 (1 mmol) in Et2O/
DMSO (2:1) was added dropwise to a stirred mixture of
NaH (0.05 g) in dry Et2O (10 ml) at room temperature and
stirring was continued for 12–14 h. Then the reaction mixture
was diluted with water and extracted with ether. The ethereal
layer was dried (an.Na2SO4) and the solvent was removed un-
der reduced pressure. The resultant solid was puriﬁed by pass-
ing through a column of silica gel (60–120 mesh) using ethyl
acetate-hexane 1:2 as eluent.
4.16. 4-Phenyl-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-pyrrole-
3-carboxamide (4a)
Yield: 90 %; mp 233–234 C; IR (t cm1, KBr): 3286 (NH),
1681 (CONH), 1577 (C‚N), 1273, 1185 (C–SC); 1H NMR(300 MHz, DMSO-d6): d 6.70 (s, 1H, pyrrole-CH), 6.76 (s,
1H, pyrrole-CH), 7.18–7.69 (m, 10H, ArH), 8.08 (bs, 1H,
CONH), 10.64 (bs, 1H, NH); 13C NMR (100 MHz, DMSO-
d6): d 109.21, 115.40, 121.82, 127.78, 128.29, 128.68, 130.02,
134.32, 137.11, 151.29, 167.53, 176.68; (ESIMS) m/z: 347
[M+H]+. Anal. Calcd. for C19H14N4OS: C, 65.88; H, 4.07;
N, 16.07. Found: C, 65.91; H, 1.04; N, 16.01.
4.17. 4-(4-Bromophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-
1H-pyrrole-3-carboxamide (4b)
Yield: 93 %; mp 209–210 C; IR (t cm1, KBr): 3292 (NH),
1693 (CONH), 1573 (C‚N), 1283, 1195 (C–SC), 613 (C–
Br); 1H NMR (300 MHz, DMSO-d6): d 6.73 (s, 1H,
pyrrole-CH), 6.79 (s, 1H, pyrrole-CH), 7.20–7.74 (m, 9H,
ArH), 8.24 (bs, 1H, CONH), 10.68 (bs, 1H, NH); 13C NMR
(100 MHz, DMSO-d6): d 109.27, 115.42, 121.80, 125.03,
127.81, 128.37, 128.92, 130.19, 130.53, 133.37, 134.35, 136.93,
151.36, 167.61, 176.71; (ESIMS) m/z: 426 [M+2H]+. Anal.
Calcd. For C19H13BrN4OS: C, 53.66; H, 3.08; N, 13.17.
Found: C, 53.62; H, 3.05; N, 13.21.
4.18. 4-(4-Nitrophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-
1H-pyrrole-3-carboxamide (4c)
Yield: 88 %; mp 199–201 C; IR (t cm1, KBr): 3297 (NH),
1695 (CONH), 1581 (C‚N), 1283, 1195 (C–SC); 1H NMR
(300 MHz, DMSO-d6): d 6.77 (s, 1H, pyrrole-CH), 6.83 (s,
1H, pyrrole-CH), 7.25–8.31 (m, 9H, ArH), 8.33 (bs, 1H,
CONH), 10.72 (bs, 1H, NH); 13C NMR (100 MHz, DMSO-
d6): d 109.66, 115.91, 119.28, 121.73, 127.86, 128.59, 128.97,
129.62, 130.21, 134.43, 144.57, 149.18, 151.43, 167.80, 176.75;
(ESIMS) m/z: 392 [M+H]+. Anal. Calcd. for C19H13N5O3S:
C, 58.30; H, 3.35; N, 17.89. Found: C, 58.33; H, 3.30; N, 17.93.
4.19. 4-(4-Fluorophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-
1H-pyrrole-3-carboxamide (4d)
Yield: 92 %; mp 220–221 C; IR (t cm1, KBr): 3294 (NH),
1690 (CONH), 1576 (C‚N), 1320 (C–F), 1268, 1205 (C–
SC); 1H NMR (300 MHz, DMSO-d6): d 6.74 (s, 1H, pyr-
role-CH), 6.81 (s, 1H, pyrrole-CH), 7.28–7.76 (m, 9H, ArH),
8.18 (bs, 1H, CONH), 10.73 (bs, 1H, NH); 13C NMR
(100 MHz, DMSO-d6): d 109.31, 115.47, 118.08, 121.83,
127.84, 128.39, 128.93, 129.38, 130.21, 133.06, 134.40, 151.37,
161.14, 167.66, 176.72; (ESIMS) m/z: 365 [M+H]+. Anal.
Calcd. for C19H13FN4OS: C, 62.63; H, 3.60; N, 15.38. Found:
C, 62.66; H, 3.63; N, 15.41.4.20. 4-(4-Iodophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-1H-
pyrrole-3-carboxamide (4e)
Yield: 89 %; mp 189–191 C; IR (t cm1, KBr): 3289 (NH),
1692 (CONH), 1574 (C‚N), 1264, 1195 (C–SC), 552 (C–
I); 1H NMR (300 MHz, DMSO-d6): d 6.74 (s, 1H, pyrrole-
CH), 6.78 (s, 1H, pyrrole-CH), 7.26–7.80 (m, 9H, ArH), 8.35
(bs, 1H, CONH), 10.65 (bs, 1H, NH); 13C NMR (100 MHz,
DMSO-d6): d 93.01, 109.18, 115.39, 121.79, 127.80, 128.36,
128.90, 129.35, 130.24, 134.30, 136.47, 137.29, 151.28, 167.58,
176.69; (ESIMS) m/z: 472 [M+H]+. Anal. Calcd. for
Synthesis and anti-inﬂammatory activity of some new 1,3,4-thiadiazoles containing pyrazole and pyrrole nucleus S311C19H13IN4OS: C, 48.32; H, 2.77; N, 11.86. Found: C, 48.30; H,
2.81; N, 11.83.
4.21. 4-(4-Chlorophenyl)-N-(5-phenyl-1,3,4-thiadiazol-2-yl)-
1H-pyrrole-3-carboxamide (4f)
Yield: 94 %; mp 215–217 C; IR (t cm1, KBr): 3288 (NH),
1690 (CONH), 1575 (C‚N), 1267, 1205 (C–SC), 713
(C–Cr); 1H NMR (300 MHz, DMSO-d6): d 6.73 (s, 1H, pyr-
role-CH), 6.79 (s, 1H, pyrrole-CH), 7.22–7.71 (m, 9H, ArH),
8.16 (bs, 1H, CONH), 10.70 (bs, 1H, NH); 13C NMR
(100 MHz, DMSO-d6): d 109.30, 115.45, 121.81, 127.82,
128.40, 128.78, 129.12, 129.84, 130.33, 134.38, 135.10, 135.52,
151.36, 167.58, 176.74; (ESIMS) m/z: 381 [M+H]+. Anal.
Calcd. for C19H13ClN4OS: C, 59.92; H, 3.44; N, 14.71. Found:
C, 59.95; H, 3.40; N, 14.67.5. Conclusion
In conclusion, we have described an efﬁcient and benign syn-
thesis of 1,3,4-thiadiazole systems containing pyrazoles and
pyrroles with good yields. 1,3,4-Thiadiazol-2-yl-acrylamide is
the key intermediate in the formation of these heterocyclic
compounds. All the synthesized compounds have been investi-
gated for their anti-inﬂammatory activity. With our newly syn-
thesized compounds, it is evident that 3c, 3d, 4c, 3f, 4d, 3b and
3e have shown excellent anti-inﬂammatory activity. Accord-
ingly, this novel class of new 1,3,4-thiadiazole derivatives re-
ported from our laboratory, emerge as a valuable lead series
with great potential to be used as anti-inﬂammatory agents,
and as promising candidates for further efﬁcacious evaluation.Acknowledgement
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